An Evaluation of Twice-Daily Dosing of Caffeine for Apnea of Prematurity.

adverse drug reaction apnea and bradycardia caffeine dosing efficacy prematurity retrospective study

Journal

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
ISSN: 1551-6776
Titre abrégé: J Pediatr Pharmacol Ther
Pays: United States
ID NLM: 101089851

Informations de publication

Date de publication:
2021
Historique:
received: 16 12 2019
accepted: 10 08 2020
entrez: 9 4 2021
pubmed: 10 4 2021
medline: 10 4 2021
Statut: ppublish

Résumé

Preterm infants often require caffeine for the treatment of apnea. While the maintenance dose of caffeine citrate is usually administered once daily per FDA labeling, many providers administer the maintenance dose in two divided doses. This study evaluated the effectiveness of a twice daily dosing regimen of caffeine for apnea of prematurity. This was a retrospective analysis conducted from 2013-2018 that included preterm infants who received caffeine that was dosed both once and twice daily respectively. The primary outcome of our study was a composite of the number of apneic and bradycardic events for five 24-hour periods prior to switching to twice daily dosing of caffeine and five 24-hour periods after switching to twice daily dosing of caffeine. The median five-day average incidence of apnea and bradycardia during the once and twice daily dosing periods was 6.2 events and 6.4 events respectively (p=0.09). There is little benefit of twice daily dosing of caffeine for apnea of prematurity.

Identifiants

pubmed: 33833626
doi: 10.5863/1551-6776-26.3.253
pmc: PMC8021238
doi:

Types de publication

Journal Article

Langues

eng

Pagination

253-257

Informations de copyright

Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.

Déclaration de conflit d'intérêts

Disclosure. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Références

Ther Drug Monit. 2008 Dec;30(6):709-16
pubmed: 19057373
J Perinatol. 2016 Feb;36(2):141-4
pubmed: 26562367
Eur J Pediatr. 2015 Jul;174(7):949-56
pubmed: 25644724
J Pediatr. 2017 Dec;191:50-56.e1
pubmed: 29173321
J Pediatr Pharmacol Ther. 2013 Jan;18(1):45-52
pubmed: 23616735
BMJ. 1994 Sep 24;309(6957):780
pubmed: 7950567

Auteurs

Classifications MeSH